Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > Hormone therapy for prostate cancer may shield from COVID-19
  • News

Hormone therapy for prostate cancer may shield from COVID-19

  • 18 May 2020
  • Elena Riboldi
Abnormal Lipid Metabolism in Prostate Cancer (Source: National Cancer Institute Purdue University Center for Cancer Research. Image by Ji-Xin Cheng)
Hormone therapy for prostate cancer may shield from COVID-19
Total
0
Shares
0
0
0
0
0
Abnormal Lipid Metabolism in Prostate Cancer (Source: National Cancer Institute Purdue University Center for Cancer Research. Image by Ji-Xin Cheng)
Prostate cancer patients treated with androgen-deprivation therapies (ADTs) seem to have a lower risk of SARS-CoV-2 infection and COVID-19 complications compared to patients not treated with ADTs and compared to other cancer patients. If confirmed, a short term treatment with ADT may be considered in male individuals at high risk of severe COVID-19. The protective role of ADTs is suggested by an Italian-Swiss group led by pharmacologist Monica Montopoli from the University of Padua and the Veneto Institute of Molecular Medicine (VIMM) in a paper just published in Annals of Oncology. The rationale behind this research is that the transmembrane protein TMPRSS2, involved in SARS-CoV-2 cell entry, is highly expressed in prostate cancer. Its expression in prostatic and non-prostatic tissues, including lung, has been shown to be regulated by the androgen receptor. Montopoli and colleagues hypothesized that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. To test this hypothesis, they analysed data from 9,280 patients (44% men) from Veneto, one of the Italian regions most affected by the COVID-19 pandemic: 430 of the male patients had a diagnosis of cancer and 118 had a diagnosis of prostate cancer. Consistently with previous reports, SARS-CoV-2-infected men had a worse clinical outcome than women. The infection was more frequent in cancer patients than in Veneto male residents without cancer. Moreover, cancer patients developed more severe disease conditions. Among prostate cancer patients receiving ADT, researchers observed a significantly lower risk of SARS-CoV-2 infections compared both to patients who did not receive ADT and to patients with any other type of cancer: only 4 out of 5,273 patients receiving ADT in Veneto developed SARS-CoV-2 infection and none of these patients died. “These data need to be further validated in additional large cohorts of SARS-CoV-2-infected patients and corrected for multiple variables – acknowledge the authors. They propose that androgen-deprivation therapies based on LHRH agonist/antagonists or AR inhibitors may be considered as a measure to reduce SARS-CoV-2 infections or complications in high-risk male populations. Given that the effects of these compounds are reversible, they could be used transiently (e.g. one month) in patients affected by SARS-CoV-2, thereby reducing the risk of side effects due to long-term administration.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • androgen deprivation therapy
  • covid-19
  • prostate
Avatar
Elena Riboldi

Previous Article
  • News

The misuse of “noninferiority” in presenting trials is often misleading

  • 11 May 2020
  • Elena Riboldi
View Post
Next Article
  • Voices

Cancer nursing, COVID-19 and healthcare inequality

  • 18 May 2020
  • Andreas Charalambous
View Post
You May Also Like
View Post
  • News

EC probe sets precedent for cancer drug price reduction

  • Janet Fricker
  • 1 March 2021
View Post
  • News

Study brings mass biparametric MRI screening for prostate cancer a step closer

  • Janet Fricker
  • 23 February 2021
View Post
  • News

Oncology providers urged to offer healthy life style advice to breast cancer survivors

  • Janet Fricker
  • 19 February 2021
View Post
  • News

Studies provide clarity on breast cancer genes for genetic panels

  • Janet Fricker
  • 9 February 2021
View Post
  • News

EC publishes route map for tackling cancer

  • Janet Fricker
  • 5 February 2021
View Post
  • News

Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers

  • Janet Fricker
  • 27 January 2021
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • EC probe sets precedent for cancer drug price reduction
    • 1 March 2021
  • Study brings mass biparametric MRI screening for prostate cancer a step closer
    • 23 February 2021
  • Oncology providers urged to offer healthy life style advice to breast cancer survivors
    • 19 February 2021
  • Studies provide clarity on breast cancer genes for genetic panels
    • 9 February 2021
  • EC publishes route map for tackling cancer
    • 5 February 2021
Latest printed issue
Article
  • Natural killers: a new tactical unit joins the cancer immunotherapy brigade
    • 25 February 2021
  • Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
    • 24 February 2021
  • Beating cancer is complex – our messaging must be clear
    • 11 February 2021
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Bridging the Age Gap in breast cancer: chemotherapy and quality of life
    • 2 March 2021
  • Moving towards efficiency in cancer care: Examples
    • 8 February 2021
  • World Cancer Day: we commemorate Professor Agim Sallaku
    • 3 February 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancer World is managed by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.